MS vs PFE: Which Is the Better Buy?
Side-by-side comparison of Morgan Stanley and Pfizer Inc. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-04-22.
Morgan Stanley · Financial Services
$189.30
-30.5% upside to fair value
Grade C
High Quality
VS
Pfizer Inc. · Healthcare
$26.91
+30.1% upside to fair value
Med Conviction
Grade B+
QuantHub Verdict
PFE has more upside to fair value
(+30.1%).
PFE trades at a lower forward P/E
(9.5x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
MS |
PFE |
| Current Price |
$189.30 |
$26.91 |
| Fair Value Estimate |
$131.49 |
$35.00 |
| Upside to Fair Value |
-30.5%
|
+30.1%
|
| Market Cap |
$300.6B |
$153.0B |
| Forward P/E |
16.4x
|
9.5x
|
| EV / EBITDA |
24.4x
|
13.8x
|
| Price / Sales |
2.5x
|
2.4x
|
| Price / FCF |
-16.8x
|
16.8x
|
| Revenue Growth YoY |
+18.8%
|
-1.6%
|
| Gross Margin |
58.0%
|
70.3%
|
| Operating Margin |
19.5%
|
24.7%
|
| Return on Equity |
16.7%
|
9.0%
|
| Dividend Yield |
0% |
6.4% |
| FCF Yield |
—
|
5.9%
|
| Analyst Consensus |
Hold
|
Hold
|
Investment Thesis
Morgan Stanley is a leading global financial services firm operating in Institutional Securities, Wealth Management, and Investment Management. The company benefits from a durable competitive moat supported by its systemically important status, diversified revenue streams, and strong management with a 36-year veteran CEO. Despite solid fundamentals including 14.2% revenue growth in 2025 and 16.7%…
Pfizer remains the world's largest traditional pharmaceutical company by non-COVID revenue, generating $62.6B in 2025 sales across oncology, cardiovascular, immunology, and vaccines. The stock trades at a P/S of 2.44x, still well below the 5-year median of 3.10x, driven by post-COVID revenue normalization, a $17-18B patent cliff spanning 2026-2028, and $61.6B in acquisition-related debt from Seag…
Accumulation Zones
| Metric |
MS |
PFE |
| Zone Low |
$98.62 |
$25.00 |
| Zone High |
$111.77 |
$29.00 |
| In Buy Zone? |
No
|
Yes
|